Bone Biologics

Bone Biologics is committed to exploring additional applications of the NELL-1 technology to enhance bone regeneration and repair in areas where the current options provide suboptimal patient outcomes.

About Us

About Us

Bone Biologics is a publicly traded company based in Burlington, MA and is focused on developing and marketing orthobiologic products. Our proprietary platform technology is NELL-1, a recombinant human protein growth factor that is essential for normal bone development.

  • Currently finalizing pivotal animal studies
  • Clearance to move into human studies in Australia
  • Potential commercialization into $3 billion dollar orthobiologics market pending successful completion of pivotal human studies in U.S
About Us

Market Overview

Bone regeneration is a significant medical challenge impacting millions of people globally.

  • Insufficient bone healing increases the likelihood of systemic medical issues and re-injury
  • The issue is becoming more pronounced as the world population continues to age and become more susceptible to bone injuries.

The orthobiologics industry with its technology advancements will benefit patients and health systems through better outcomes, reduced surgical time, faster healing, and reduced costs.

With an aging population, musculoskeletal diseases are becoming a greater burden as the cost of treating long-term pain and disability increases. Musculoskeletal disease exceeds cancer by 6x.

Source: National Health Interview Survey

Bone Biologics Corp. Advantages

Opportunity

  • 3 billion global market opportunity in spine fusion
  • Additional indications in trauma and osteoporosis

Business

  • A lean, virtual business model with leading
  • strategic partners, vendors, and contractors

Technology

  • Strong technology discovered at UCLA
  • Proprietary product platform with strong IP

Regulatory Path

  • A device/drug combo with device on lead
  • Following medical device PMA tract to FDA approval

Pre-Clinical Data

  • Pre-clinical studies have shown increases in
  • fusion and quantity of bone

Management Team

Jeff Frelick

Chief Executive Officer | President

Jeff Frelick

Jeffrey Frelick assumed the CEO and President role in June 2019. Previously he served as the Chief Operating Officer of Bone Biologics Inc. since August 2015. Frelick brings more than 25 years of med-tech experience to the position. He spent the past 15 years on Wall Street as a sell-side analyst following the med-tech industry at investment banks such as Canaccord Genuity, ThinkEquity and Lazard. Prior to becoming an equity research analyst, Frelick worked at Boston Biomedical Consultants where he provided strategic planning assistance, market research data and due diligence for diagnostics companies. He previously held sales and sales management positions at Becton Dickinson’s Primary Care Diagnostic Division after gaining technical experience as a laboratory technologist with Clinical Pathology Facility. Frelick earned a B.S. in Biology from the University of Pittsburgh and an M.B.A. from Suffolk University’s Sawyer Business School.

Deina Walsh

Chief Financial Officer

Deina Walsh was appointed CFO of Bone Biologics in October 2014. Walsh is a certified public accountant and owner/founder of DHW CPA, PLLC a Public Companies Accounting Oversight Board (PCAOB) registered firm since 2014. Prior to forming her firm, Walsh spent 13 years at a public accounting firm where she was actively responsible for leading firm audit engagements of publicly held entities in accordance with PCAOB standards and compliance with SEC regulations, including internal control requirements under section 404 of the Sarbanes-Oxley Act. Her experience includes work with start-up companies and well-established operating entities. She has assisted many entities seeking debt and equity capital. Areas of specialty include mergers, acquisitions, reverse mergers, consolidations, complex equity structures, foreign currency translations and revenue recognition complexities. Walsh earned an A.S. in Business Administration from Monroe Community College and a B.S. in Accounting from the State University of New York at Brockport.

Brent Atkinson, Ph.D.

R&D Consultant

BrentAtkinson

Dr. Atkinson has over 25 years of leading product development, clinical, and regulatory experience in the orthopedic industry. He was previously vice-president of R&D at AlloSource and vice-president of product development at BioSET. He also held roles of Director of R&D at Dentsply and product development scientist at Sulzer Biologics. Dr. Atkinson received his Ph.D. in molecular biology from Columbia University.

Board of Directors

Don R. Hankey, Chairman

CEO/Chairman, Hankey Group

Don Hankey

Mr. Hankey holds his BA and post-graduate work from the University of Southern California. At age 27, Mr. Hankey became Vice President of a major investment banking firm, which would later become part of USB Paine Weber. Mr. Hankey acquired Midway Ford in 1972 and founded Hankey Investment Company in 1982. During the 1980s Mr. Hankey’s organization grew its portfolio and established a foothold in the financial services industry. Mr. Hankey has incorporated technology into every aspect of the Hankey Group of companies improving efficiencies and outcomes. Mr. Hankey has been the manager of Hankey Capital, LLC, since its formation in 2002.

Bret Hankey, Director

President, Hankey Group

Bret Hankey

Mr. Hankey brings more than 15 years of operating and board director experience to the BBLG board. Since 2000, Mr. Hankey has served in various capacities within the Hankey Group where he currently serves as President and is a member of the board of directors on all seven operating companies specializing primarily in the automotive, finance, technology, real estate and insurance industries.

Bruce Stroever, Director

Former CEO, Musculoskeletal Transplant Foundation

Bruce Stroever

Mr. Stroever has forty years of product development and general management experience in the medical device and orthobiologics fields. Mr. Stroever joined MTF in late 1988 as General Manager and retired in mid-2018 from his position as the President and Chief Executive Officer of MTF. He served as MTF’s President since his appointment in 1992 and as Chief Executive Officer since 1996. Under Mr. Stroever’s leadership, MTF grew to be the largest tissue bank in the world providing over 500,000 grafts per year with revenues over $400 million. From 1971 to 1988, Mr. Stroever held several positions with Ethicon, Inc., a Johnson & Johnson, Inc. subsidiary. Mr. Stroever currently serves on the advisory board for the New Jersey Organ and Tissue Sharing Network. He was elected to the Board of Governors of the American Association of Tissue Banks for a three year term in 1999 and subsequently in 2012. He was a founding member of the Tissue Policy Group subsidiary of the AATB and served as its Chairman for two terms. Mr. Stroever served as the Chairman of the Bone Biologics Board of Directors from 2012 through mid-2018. Mr. Stroever received his B.E. in Mechanical/Chemical Engineering from Stevens Institute of Technology in 1972 and a Masters of Science in Bioengineering from Columbia University in 1977.

Stephen R. La Neve

Executive VP, International at Globus Medical

Stephen La Neve

Mr. La Neve brings 35 years of health care experience and leadership to Bone Biologics. Previously Mr. La Neve was CEO of Bone Biologics, Life Science Enterprises, and ETEX Corp. while holding divisional president roles at Medtronic and Becton Dickinson. He holds a B.S. in Health Planning from Penn State University and an MBA from West Chester University.